S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
ONCO$0.5258-3.13%
Onconetix, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$2.76M
Float & O/S:
Inst Own:
DilutionScan read 30 of Onconetix, Inc.'s SEC filings and found 7 warrant series, 5 convertibles, 1 ATM program, 2 equity lines, 8 S-1 registrations and 4 completed offerings on file for ONCO. The latest dilution event on file is a registration statement on Sep 3, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
ONCO
Going-concern warning and reverse splits
Snapshot
Onconetix is a distressed micro-cap biotech fighting for survival. FY 2025 revenue collapsed 68% to $815K, while the company burned $9.7M in free cash flow. With only $5.2M in the bank, the cash runway is under one month.
What's Happening Right Now
- : Onconetix filed an S-1 registration disclosing substantial doubt about its ability to continue as a going concern, while registering up to 100 million shares for resale under an equity line.
- : The board approved a 1-for-10 reverse stock split effective May 21, 2026, the second reverse split in three months.
- : Subsidiary Proteomedix initiated a multi-center clinical validation study for its Proclarix diagnostic test in collaboration with Labcorp.
- : Onconetix announced it entered a definitive agreement to acquire Realbotix LLC, a subsidiary developing humanoid robots and AI vision systems.
Raise routes on file: active ATM + effective S-1 + active equity line · latest dilution event 61 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Sep 3, 2026 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
Series D Warrants (September 22, 2025 Series D PIPE)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series E Warrants (October 1, 2025 Series E PIPE)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series C Warrants (October 2, 2024 Series C PIPE)
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series F Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series D Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series C Convertible (Redeemable) Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Series E Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2023
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
Equity line
Issued 2024
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
Equity line
Issued 2026
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
PIPE
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your ONCO trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
